Yahoo Web Search

Search results

1. www.gene.comGenentech

   www.gene.com

   • Cached

   Genentech is a biotechnology company that develops and delivers innovative medicines for serious diseases. Learn about its pipeline, research, patient support, and social responsibility initiatives.

   • Advancing Inclusive Research

     Advancing Inclusive Research ® (AIR) is an innovative...

   • Patient Financial Support

     If you need help understanding your health insurance...

   • Clinical Trial Information

     In rare circumstances, Genentech may provide patients with...

   • Our Pipeline

     Pipeline. Rigorous and groundbreaking science has always...

   • Our Medicines

     You may also report side effects to Genentech at (888)...

   • Featured Topics

     Find Genentech stories by topic. Find Genentech stories by...

   • Hematology

     Find Genentech stories by topic. Hematology. Learn about the...

   • Genentech: Media

     On October 4, 2018, the FDA approved a Genentech medicine as...

2. en.wikipedia.org › wiki › GenentechGenentech - Wikipedia

   en.wikipedia.org › wiki › Genentech

   • Cached

   Genentech is a subsidiary of Roche that was founded in 1976 by Robert Swanson and Herbert Boyer, pioneers in recombinant DNA technology. It develops and produces biologic drugs for various diseases, such as cancer, autoimmune, and infectious diseases.

3. Videos

   • 

     1:41

     youtube.com

     The HER Signaling Pathway

     13 Nov 2012

     54.2K views

   • 

     2:13

     youtube.com

     Genentech Gives Back 2023

     24 Oct 2023

     831 views

   • 

     1:54

     youtube.com

     The MAPK Signaling Pathway

     13 Nov 2012

     188.8K views

   View all

4. www.gene.com › about-usAbout Us - Genentech

   www.gene.com › about-us

   • Cached

   Genentech is a biotechnology company that discovers and develops medicines for serious and life-threatening diseases. Learn about its history, mission, values, and podcast series on human biology.

5. www.gene.com › medical-professionals › medicinesMedicines and Products - Genentech

   www.gene.com › medical-professionals › medicines

   • Cached

   Find prescribing information, medication guides, healthcare provider letters, and safety data sheets for Genentech's biologic products. Browse by product name, indication, or therapeutic area.

6. Top stories

   • 

     Genentech acquires Regor’s next-gen CKD inhibitor portfolio

     Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth $850M.

     emjreviews.com

     1 day ago

   • 

     YAHOO!Finance

     Genentech buys Regor’s CDK inhibitors in $850m deal

     2 days ago

   • 

     The Reporter

     Lonza finalizes $1.2 billion Genentech deal

     15 hours ago

   • 

     pharmaphorum

     Genentech buys Regor's next-gen CDK inhibitors for $850M

     3 days ago

   • FierceBiotech

     Roche celebrates Pharma Day by buying Regor's CDK inhibitors, regenerative med-focused AntlerA

     3 days ago

   View all

7. www.roche.com › innovation › structureGenentech R&D (gRED) - Roche

   www.roche.com › innovation › structure

   • Cached

   Genentech is a leading biotechnology company that discovers and develops medicines for serious and life-threatening diseases. It is part of the Roche Group since 2009 and has its headquarters in South San Francisco, USA.

8. www.linkedin.com › company › genentechGenentech - LinkedIn

   www.linkedin.com › company › genentech

   Genentech is a biotechnology company that creates and delivers innovative medicines for various conditions. Learn about its history, specialties, locations, employees, updates, and promise on LinkedIn.

9. finance.yahoo.com › news › fda-approves-genentechs-alecensaFDA Approves Genentech's Alecensa as First Adjuvant Treatment for...

   finance.yahoo.com › news › fda-approves-genentechs-alecensa

   • Cached

   Apr 18, 2024 · Alecensa is the first and only ALK inhibitor approved by the FDA for adjuvant treatment of ALK-positive NSCLC following surgery. The approval is based on a Phase III study showing a 76% reduction in disease recurrence or death with Alecensa compared to placebo.